Bronchogen
Pesquisa moderadaAEDL Tetrapeptide | Bronchial Bioregulator
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St.
Dados moleculares e de pesquisa
- Sequência
- Ala-Glu-Asp-Leu
- Peso molecular
- 432 Da
- Meia-vida
- Minutes (short peptide); effects persist via epigenetic changes
- Vias (pesquisa)
- oral, injectable
- Armazenamento
- Oral capsules: room temperature. Injectable: 2-8°C refrigerated
Overview
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia’s St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.
Mechanism of action
Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.
Key research findings
- Supports bronchial tissue function
- Regulates protein synthesis in lungs
- Targets bronchopulmonary system
- Maintains respiratory epithelium
- Part of Khavinson bioregulator family
- Epigenetic mechanism of action
- Tissue-specific targeting
- Well-tolerated in research
Research applications
Respiratory Support
- Bronchial Function — Supports bronchial tissue through gene expression regulation.
- Respiratory Maintenance — Helps maintain respiratory epithelium health.
- Pulmonary Health — Regulates protein synthesis in lung tissue.
Anti-Aging
- Respiratory Aging — Addresses age-related changes in bronchial tissue.
- Gene Expression — Modulates gene expression in respiratory cells.
FAQ de Bronchogen
How do Khavinson bioregulator peptides work if their half-life is just minutes?+
Bronchogen's tetrapeptide structure allows it to penetrate cell nuclei directly and modulate gene expression epigenetically. Despite its short circulating half-life, it triggers lasting changes in DNA regulation and protein synthesis in bronchial tissue. These epigenetic changes persist long after the peptide itself clears circulation.
What respiratory benefits have been proven in human trials for Bronchogen?+
Clinical evidence on Bronchogen specifically is limited. Most research comes from Russian sources showing improvements in respiratory function when combined with other Khavinson peptides. Clear human efficacy data from double-blind trials doesn't exist in English-language literature.
Can I combine Bronchogen with other respiratory support supplements?+
Yes. Bronchogen's epigenetic mechanism complements other approaches. It pairs well with standard respiratory support compounds, though no specific clinical data on combinations exists. Other Khavinson peptides like Chonluten target related respiratory systems synergistically.
How long before I notice respiratory improvements on Bronchogen?+
Bronchogen works through gene expression changes that occur during the 10-20 day cycle. Noticeable respiratory improvements typically emerge weeks to months after cycles complete as the epigenetic changes take effect. Results improve with repeated 2-3 cycles yearly for cumulative benefits.
References
Peptídeos relacionados
Chonluten
Moderate researchEDG Tripeptide | Bronchial/Lung Bioregulator
Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St.
Crystagen
Moderate researchEDP Tripeptide | Thymus Immune Bioregulator
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St.
Glutathione
Extensively studiedL-Glutathione | Master Antioxidant Tripeptide
Glutathione is the body's master antioxidant, a tripeptide produced naturally by the liver.
KPV
Emerging researchAnti-Inflammatory Tripeptide | Alpha-MSH Fragment
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH.